Elevance Raises 2026 Earnings Guidance Following Strong Q3 Performance
During its third-quarter 2026 earnings call, Elevance (ELV) announced an increased full-year earnings baseline of at least $26.75 per share, a $0.75 increase driven by strong operating performance and favorable claims in Individual ACA health plans. Management highlighted that Medicaid rates are aligning with medical costs, providing better visibility for long-term growth. The company is leveraging its Carelon healthcare services unit to drive margin expansion through clinical management tools. Specifically, integrated cancer care programs have successfully reduced avoidable inpatient admissions by 15% in the commercial market. Additionally, the integration of pharmacy and medical coverage has resulted in savings of up to $100 per member per month for employer groups. Looking forward, Elevance expects stable medical cost trends across Medicaid and commercial lines. The company aims to utilize its scale and digital platforms to improve pricing discipline and medical cost control, positioning itself for sustainable long-term earnings growth beyond 2027.